Experimental 'Off-the-Shelf' CAR-T therapy takes on tough lymphoma
NCT ID NCT07563543
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to other treatments. RN1701 is a type of immune cell therapy made from donor cells, designed to target two markers on cancer cells. The study will enroll about 10 participants to check if the treatment is safe and to get an early look at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RN1701 (a type of immune cell therapy called CAR-T, made from donor cells and targeting two proteins on cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell lymphomas that have not responded to standard therapies.
What could go wrong
This is a very early, small study (only 10 participants) focused on safety, so it is uncertain if it will work. There are risks of serious side effects like cytokine release syndrome and nervous system problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••